Stephanie Tubbs Jones Uterine Fibroid Research and Education Act
Title VII — Addressing high-impact minority diseases › Subtitle D — Cardiovascular disease, chronic disease, obesity, and other disease issues
Read this section in the full bill →
This section appears in one version only, so there is nothing to compare yet.
(a) Research with respect to uterine fibroids (1) Research The Secretary of Health and Human Services (referred to in this section as the Secretary) shall expand, intensify, and coordinate programs for the conduct and support of research with respect to uterine fibroids. (2) Administration and coordination The Secretary shall carry out the conduct and support of research pursuant to paragraph (1), in coordination with the appropriate institutes, offices, and centers of the National Institutes of Health and any other relevant Federal agency, as determined by the Director of the National Institutes of Health. (3) Authorization of appropriations For the purpose of carrying out this subsection, there are authorized to be appropriated $30,000,000 for each of fiscal years 2027 through 2031. (b) Research with respect to medicaid coverage of uterine fibroids treatment (1) Research The Secretary (or the Secretary’s designee) shall establish a research database, or expand an existing research database, to collect data on services furnished to individuals diagnosed with uterine fibroids under a State plan (or a waiver of such a plan) under the Medicaid program under title XIX of the Social Security Act (42 U.S.C. 1396 et seq.) or under a State child health plan (or a waiver of such a plan) under the Children’s Health Insurance Program under title XXI of such Act (42 U.S.C. 1397aa et seq.) for the treatment of such fibroids for purposes of assessing the frequency at which such individuals are furnished such services. (2) Report (A) In general Not later than 2 years after the date of enactment of this Act, the Secretary shall submit to Congress a report on the amount of Federal and State expenditures with respect to services furnished for the treatment of uterine fibroids under State plans (or waivers of such plans) under the Medicaid program under such title XIX and State child health plans (or waivers of such plans) under the Children’s Health Insurance Program under such title XXI. (B) Coordination The Secretary shall coordinate the development and submission of the report required under paragraph (1) with any other relevant Federal agency, as determined by the Secretary. (c) Education and dissemination of information with respect to uterine fibroids (1) Uterine fibroids public education program The Secretary shall develop and disseminate to the public information regarding uterine fibroids, including information on— (A) the awareness, incidence, and prevalence of uterine fibroids among individuals, including all minority individuals; (B) the elevated risk for minority individuals to develop uterine fibroids; and (C) the availability, as medically appropriate, of the range of treatment options for symptomatic uterine fibroids, including non-hysterectomy treatments and procedures. (2) Dissemination of information The Secretary may disseminate information under paragraph (1) directly or through arrangements with intra-agency initiatives, nonprofit organizations, consumer groups, institutions of higher education (as defined in section 101 of the Higher Education Act of 1965 (20 U.S.C. 1001)), or Federal, State, or local public private partnerships. (3) Authorization of appropriations For the purpose of carrying out this subsection, there are authorized to be appropriated such sums as may be necessary for each of fiscal years 2027 through 2031. (d) Information to health care providers with respect to uterine fibroids (1) Dissemination of information The Secretary shall, in consultation and in accordance with guidelines from relevant medical societies, work with health care-related specialty societies and health systems to promote evidence-based care for individuals with fibroids. Such efforts shall include minority individuals who have an elevated risk to develop uterine fibroids and the range of available options for the treatment of symptomatic uterine fibroids, including non-hysterectomy drugs and devices approved under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.). (2) Authorization of appropriations For the purpose of carrying out this subsection, there are authorized to be appropriated such sums as may be necessary for each of fiscal years 2027 through 2031. (e) Definition In this section, the term minority individuals means individuals who are members of a racial and ethnic minority group, as defined in section 1707(g) of the Public Health Service Act (42 U.S.C. 300u–6(g)).